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Hyperlactatemia After Intracranial Tumor Surgery Does
Not Affect 6-Month Survival: A Retrospective Case Series
Peter P. de Smalen, MD,* Tom J. van Ark, BSc,* Robert J. Stolker, MD, PhD,*
Arnaud J.P.E. Vincent, MD, PhD,† and Markus Klimek, MD, PhD, DEAA, EDIC*
Background: Patients undergoing neurosurgery frequently exhibit
hyperlactatemia. The aim of this study was to identify factors
associated with hyperlactatemia and assess how hyperlactatemia
impacts survival and hospital length of stay after intracranial
tumor surgery.
Materials and Methods: This retrospective cohort study in-
cluded 496 adult patients that underwent surgery between
January 1, 2014 and December 31, 2015. We evaluated patient
characteristics, surgery characteristics, pH, lactate, and blood
glucose from blood samples collected on admission to the high-
dependency unit and the morning after surgery, and 6-month
outcome data.
Results: Hyperlactatemia (> 2.0mmol/L) occurred in > 50% of
patients, but only 7.7% had acidosis. Postoperative hyper-
lactatemia was not correlated with 6-month survival (P= 0.987),
but was correlated with (median [interquartile range]) longer hos-
pital stays (6 [4 to 8.5] d vs. 5 [4 to 8] d; P= 0.006), longer surgery
duration (4:53 [4:01 to 6:18] h:min vs. 4:28 [3:33 to 5:53] h:min;
P= 0.001), higher dexamethasone dose (16 [16 to 35] mg vs. 16 [16
to 20]mg; P< 0.001), and higher blood glucose concentration (8.4
[7.5 to 9.6] mmol/L vs. 8.0 [7.1 to 8.9] mmol/L; P< 0.001). Patients
that received total intravenous anesthesia developed hyper-
lactatemia less frequently than those that received balanced anes-
thesia with inhalational agents (48.4% vs. 61.5%, P= 0.008).
Hyperlactatemia was not associated with increased postoperative
neurological deﬁcits or the need for rehabilitation therapy.
Conclusions: Hyperlactatemia was common after intracranial
tumor surgery. It did not inﬂuence 6-month outcomes but was
associated with longer hospital length of stay. Several potential
causative factors for hyperlactatemia were identiﬁed.
Key Words: neurosurgery, hyperlactemia, lactic acidosis,
dexamethasone, 6-month survival
(J Neurosurg Anesthesiol 2020;32:48–56)
Lactic acidosis (hyperlactatemia type A) is a life-threatening clinical state.1,2 However, little is known
about the contributing factors and prognosis of elevated
serum lactate without acidosis, also called hyperlactatemia
type B.3 Hyperlactatemia type B is frequently observed
in patients undergoing neurosurgery, but it is unclear
whether it affects patient outcomes.4,5 Brallier et al6
reported that hyperlactatemia was associated with pro-
longed hospital length of stay and new neurological deﬁ-
cits. Another study found that high-grade brain tumors
were associated with elevated serum lactate before treat-
ment, and that elevated serum lactate was correlated with
poor progression-free and overall survival.7 A conclusive
view on the causes and implications of hyperlactatemia in
neurosurgery remains to be determined.
Several studies have identiﬁed factors associated
with elevated lactate levels in patients undergoing
neurosurgery.5,8–14 These include the use of volatile anes-
thetic agents, surgery duration, tumor volume, cortico-
steroids, diuretics, body mass index (BMI), and mannitol
infusion. As expected, the use of dexamethasone, which is
common in patients undergoing brain tumor surgery, has
been identiﬁed as a cause of elevated serum lactate.15,16
Another substance of special interest in this patient pop-
ulation is mannitol, which is partly metabolized to gly-
cogen in the liver. However, studies have not consistently
found a signiﬁcant increase in serum lactate related to
mannitol infusion.10,11,17,18 In contrast to the afore-
mentioned factors, propofol has been reported to cause
hyperlactatemia type A, which might be related to the
propofol infusion syndrome (PRIS).19 An overview of the
relevant literature is provided in Supplemental Digital
Content 1, http://links.lww.com/JNA/A114.
Most previous studies that focused on patients un-
dergoing neurosurgery have analyzed only small pop-
ulations, which limited the validity of their conclusions.
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The present study includes the large Rotterdam neuro-
surgery population, and we mirrored assessments per-
formed in previous studies. The primary outcome of this
study was the effect of hyperlactatemia on 6-month sur-
vival. Secondary outcomes included the identiﬁcation of
factors potentially associated with a rise in serum lactate,
both immediately postoperatively and on the morning
after surgery. Finally, we examined differences in clinical
outcomes between patients with and without elevated
lactate-hospital length of stay, postoperative worsening of
neurological status, and need for rehabilitation therapy.
MATERIALS AND METHODS
This study was approved by the Institution’s Medi-
cal Ethics Committee: reference MEC-2016-125. Because
we used anonymous data recorded in the patient data
management system, according to Dutch law no formal
informed consent was required.
We retrieved data for all patients that underwent
neurosurgery at the Erasmus University Medical Center,
Rotterdam, between January 1, 2014 and December 31,
2015. We conducted a computerized search to select pa-
tients with an intracranial tumor based on surgical cod-
ing. We included (stereotactic) biopsies, intracranial
tumor surgery, and pituitary adenoma surgery. We ini-
tially identiﬁed a total of 759 cases, but some procedures
were double coded so there were 739 patients for inclusion
screening. When patients underwent multiple surgeries
within the study period, only the ﬁrst procedure was
included. Despite the digital coding, 52 cases did
not undergo intracranial tumor surgery according to the
chart records; these patients were excluded from the study
population. Cases in which lactate was not measured
or data were unavailable were also excluded (n= 143),
as were patients that underwent awake craniotomy.
Finally, 496 cases were available for inclusion in the study
(Fig. 1).
Data Collection
We collected data on patient characteristics; that is,
age, weight, height, American Society of Anesthesiologists
(ASA) physical status classiﬁcation, and duration of hospital
stay (deﬁned from the day of surgery until discharge). We
also collected data on tumor characteristics such as location,
pathologic type, and extent of resection. The latter was ex-
tracted from the surgery reports and postoperative magnetic
resonance imaging scans. Tumor tissues detected macro-
scopically or radiologically were considered tumor remnants.
Nearly complete resection was deﬁned as an unclear margin
or recurrence detected in a subsequent scan, and complete
resection as the absence of recurrence in multiple magnetic
resonance imaging scans.
We also collected perioperative information, including
operation duration, blood loss, ﬂuid balance, drugs ad-
ministered (eg, dexamethasone and mannitol), and anes-
thesia type. General anesthesia for this type of surgery was
not standardized; patients received either total intravenous
anesthesia (TIVA) or balanced anesthesia. For all cases in-
volving TIVA, induction was performed with a bolus of
propofol. Analgesia during induction was provided mostly
with remifentanil infusion but, in some cases, with sufenta-
nil. Anesthesia was maintained with remifentanil and pro-
pofol infusions. Balanced anesthesia included induction with
sufentanil and propofol, and maintenance with sufentanil
and inhalational agents (mainly sevoﬂurane). Desﬂurane,
nitrous oxide, and dexmedetomidine were not used in any
patient. All intravenous ﬂuids were lactate free.
We also collected data on self-reported new post-
operative neurological deﬁcits and the need for rehabilitation
therapy. This was based on a questionnaire which is
described in detail in a previous manuscript that focused on
the neuropsychological aspects of brain tumor resections in
the same patient cohort.20
Finally, we retrieved 6-month survival data from our
hospital’s patient data management system, which is reg-
ularly updated with input from governmental sources.
Digital coding for
intracranial tumor surgery
in 2014-2015
N=759
Double coding for the same
procedure. N =20
No intracranial tumor
surgery. N=52
Second procedure within
study time frame. N=13
No lactate measured. N=143
Awake craniotomy. N=35
Included
N=496
Normal lactate
N=239
Hyperlactatemia
N=257
FIGURE 1. Flow chart of patients included in the study.
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Blood Sampling for Measurement of Lactate,
pH, and Glucose
Laboratory blood tests were collected by an arterial
cannula at standardized times as part of our routine pa-
tient care for this type of surgery. All patients were
transferred to a high-dependency unit (HDU) or intensive
care unit (ICU) at the end of surgery. The HDU in our
hospital is an environment with intensive care treatment
facilities, but admission is limited to those with an ex-
pected need of care for <24 hours. For intracranial tumor
surgery, only patients with tumors in the posterior cranial
fossa, with evident or potential compression of the
brainstem, or at high risk of bleeding are admitted to the
ICU. The therapeutic protocols in the HDU and ICU are
identical so we grouped the patients of both units together
and refer to this as the HDU. Arterial blood samples were
taken upon admission to the HDU and on the morning
after surgery and we retrieved data on pH, lactate, and
blood glucose. Serum lactate 2.0 mmol/L or lower was
considered normal and pH< 7.35 considered acidosis.
There was no routine preoperative blood sampling. For
patients registered as deceased, we calculated the time
between surgery and death, and this was included in the
6-month survival evaluations.
Statistical Analysis
Numerical variables were tested for normality by
visual inspection of histograms and Q-Q plots and with
the Shapiro-Wilk test. All continuous variables were not
normally distributed and we therefore report medians and
interquartile ranges (IQR). Analysis for dichotomous
outcome was performed using a Mann-Whitney test. The
population was divided into 4 groups, reﬂecting the course
of lactate levels between HDU admission and the morning
after surgery: (1) Normal lactate on admission and the
morning after surgery; (2) hyperlactatemia on admission,
but normal lactate on the morning after surgery; (3) hy-
perlactatemia on admission, that persisted on the morning
after surgery; (4) normal lactate on admission, that had
become elevated by the morning after surgery. For this
analysis a Kruskal-Wallis test was used. For all catego-
rical data we used a χ2 test, except for the ASA classi-
ﬁcation, where a Fisher exact test was performed.
A P-value of <0.05 was considered signiﬁcant.
We performed a regression analysis to quantify the
relative contribution of the inﬂuencing factors. This was
also performed multivariate, to correct for confounding
variables. We corrected for all parameters that were sus-
pected of inﬂuencing the production of lactate, based on
review of the literature. These parameters included: age,
BMI, surgery duration, blood loss, ﬂuid balance, total
dexamethasone dose, total mannitol dose in g/kg, glucose
on HDU admission, pH on HDU admission, tumor type,
and anesthesia type.
All data were collected by 2 of the authors, and any
inconsistencies were openly discussed. Processing and
statistics were performed with IBM SPSS Statistics version
23 (IBM Corp., Armonk, NY).
RESULTS
Of the 496 patients included in the study, 15 (3%) had
undergone tumor biopsy and 22 (4.4%) a ﬁrst intracranial
surgery before the study period. Unfortunately, not all data
could be extracted from all medical ﬁles; where relevant, we
indicated the respective number of patients.
The questionnaire response rate was 57% (272 of 476
patients). Our previous study excluded 23 patients from
analysis because they were deceased at the time of receiving
the questionnaire.20 The questionnaire response was 180
patients for neurological change and 214 for rehabilitation.
Owing to our exclusion criteria we were able to include data
on 160 patients for neurological outcome and 191 for re-
habilitation needs. Of the patients included in our study, 121
(76%) reported decreased or unchanged neurological deﬁcits
and 115 (60%) no need for rehabilitation.
At HDU admission 257 (51.8%) patients had serum
lactate levels above the normal upper limit (2.0 mmol/L)
and 86 had acidosis (pH< 7.35); 38 (7.7%) patients had
both acidosis and hyperlactatemia. Only 2 (0.4%) patients
had a pH< 7.25. On the basis of the lactate and pH
ﬁndings, we concluded that we identiﬁed mainly hyper-
lactatemia type B.
Of the patients with elevated lactate upon admission
to the HDU, 72.7% had normalized lactate levels by the
following morning. We found no association between hy-
perlactatemia upon arrival to the HDU and reduced sur-
vival at 6 months (Table 1). Patients with hyperlactatemia
had a median hospital stay of 6 (IQR: 4 to 8.5) days,
compared with 5 (IQR: 4 to 8) days for patients without
hyperlactatemia (P= 0.006). The 2 groups were similar in
their self-reported worsening of neurological status (23.2%
vs. 25.6%, P= 0.716) and need for rehabilitation (39.2% vs.
40.4%, P= 0.860).
Compared with those with normal lactate levels, pa-
tients with hyperlactemia on admission to the HDU had
signiﬁcantly longer surgery durations, greater blood loss,
less positive ﬂuid balance, higher dose of dexamethasone
administration, and higher blood glucose (Table 2).
Moreover, patients with elevated serum lactate upon
arrival to the HDU had signiﬁcantly higher lactate levels
the morning after surgery compared with those with normal
TABLE 1. Outcomes of Patients Who Underwent
Neurosurgery and, Upon Arrival to the HDU, Had Normal
(≤2mmol/L) or Elevated (>2mmol/L) Serum Lactate
Outcome
Parameters N
Normal Lactate
(N= 239)
Elevated Lactate
(N= 257) P
Length of stay (d) 496 5 (4-8) 6 (4-8.5) 0.006*
Increased
neurological
deﬁcits
160 20 (25.6) 19 (23.2) 0.716
Rehabilitation
necessary
191 38 (40.4) 38 (39.2) 0.860
6-mo survival 496 201 (84.1) 216 (84.0) 0.987
Values are the median (IQR) or number of patients (% of group total).
HDU indicates high-dependency unit; IQR, interquartile range.
*P< 0.05.
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lactate at HDU admission. Interestingly, despite the
elevated lactate levels these patients also had signiﬁcantly
higher pH than those with normal serum lactate on the
morning after surgery.
Although there was no signiﬁcant association be-
tween tumor type and serum lactate levels at HDU ad-
mission, the following trend was identiﬁed: patients with
glioblastoma had elevated lactate more often than those
with meningioma, astrocytoma, oligodendroglioma, or
medulloblastoma. Patients that received TIVA had hy-
perlactatemia less frequently than those that received
balanced anesthesia (48.4% vs. 61.5%, P= 0.008). The
balanced anesthesia group received sevoﬂurane (65.7%) or
isoﬂurane (34.3%) as maintenance anesthetic.
After identifying factors that contributed to hyper-
lactatemia on admission to HDU, we tested these factors for
hyperlactatemia on the day after surgery and performed a
logistic regression to quantify the size of the effect (Table 3).
We also calculated the adjusted odds ratio, corrected for the
confounders shown in the table. On the morning after
surgery, 79 patients (17%) had hyperlactatemia; this included
those with hyperlactatemia that persisted (n=65) and those
with a newly elevated lactate (n=14). Complete descriptive
characteristics of the patients in the 4 groups, based on their
serum lactate at HDU admission and the morning after
surgery, are shown in Table 4.
The multiple regression analysis revealed that age,
surgery duration, amount of dexamethasone administered,
and blood glucose upon arrival to the HDU persisted as
signiﬁcant independent factors related to hyperlactatemia at
HDU admission. In contrast, blood loss and ﬂuid balance
were not independently related to hyperlactatemia at HDU
admission. Furthermore, we found that the use of TIVA was
associated with reduced risk of hyperlactatemia at HDU
admission compared with balanced anesthesia. Patients
with a meningioma, astrocytoma, oligodendroglioma, or
TABLE 2. Characteristics of Patients That Underwent Neurosurgery, Divided Into Groups of Normal (≤2mmol/L) or Elevated
(>2mmol/L) Serum Lactate at HDU Admission
Variables N Normal Lactate (N= 239) Elevated Lactate (N= 257) P
Age (y) 496 59.3 (48.3-69.3) 58.8 (47.4-67.5) 0.279
BMI (kg/m2) 496 25.7 (23.0-28.8) 26.0 (23.7-29.4) 0.116
Surgery duration (h:min) 496 4:28 (3:33-5:53) 4:53 (4:01-6:18) 0.001*
Blood loss (mL) 496 200 (100-400) 300 (150-500) 0.001*
Fluid balance (mL) 484 376 (−52 to 734) 185 (−371 to 655) 0.008*
Total dexamethasone administered (mg) 482 16 (16-20) 16 (16-35) < 0.001*
Total mannitol administered (g) 483 30 (0-45) 30 (15-45) 0.890
Total mannitol administered per kilogram (g/kg) 483 0.38 (0-0.63) 0.37 (0.17-0.54) 0.596
Glucose on HDU admission (mmol/L) 494 8.0 (7.1-8.9) 8.4 (7.5-9.6) < 0.001*
Lactate on HDU admission (mmol/L) 496 1.4 (1.0-1.6) 2.9 (2.4-3.6) < 0.001*
pH on HDU admission 492 7.39 (7.36-7.41) 7.39 (7.37-7.42) 0.119
Glucose morning after admission (mmol/L) 482 7.0 (6.3-7.8) 7.1 (6.4-8.1) 0.089
Lactate morning after admission (mmol/L) 459 1.2 (0.9-1.6) 1.7 (1.4-2.1) < 0.001*
pH morning after admission 473 7.43 (7.41-7.45) 7.44 (7.41-7.46) 0.002*
Tumor type 496 0.055
Glioblastoma 55 (23.0%) 82 (31.9%)
Meningioma (WHO I-III) 72 (30.1%) 56 (21.8%)
Astrocytoma, oligodendroglioma, medulloblastoma 34 (14.2%) 23 (8.9%)
Adenoma, craniopharyngioma, cyst 27 (11.3%) 27 (10.5%)
Ependymoma, schwannoma, hemangioblastoma 11 (4.6%) 15 (5.8%)
Metastasis 32 (13.4%) 47 (18.3%)
Lymphoma, other 8 (3.3%) 7 (2.7%)
ASA class 496 0.404
I 33 (13.8%) 44 (17.1%)
II 157 (65.7%) 153 (59.5%)
III 45 (18.8%) 58 (22.6%)
IV 3 (1.3%) 2 (0.8%)
V 1 (0.4%) 0 (0.0%)
Tumor side 496 0.565
Left 99 (41.4%) 98 (38.1%)
Right 105 (43.9%) 113 (44.0%)
Both (eg, pituitary) 35 (14.6%) 46 (17.9%)
Degree of resection 493 N= 237 N= 256 0.177
Complete resection 58 (24.5%) 54 (21.1%)
Nearly complete resection 35 (14.8%) 27 (10.5%)
Tumor remnant 144 (60.8%) 175 (68.4%)
TIVA 484 N= 231 N= 253 0.008*
176 (76.2%) 165 (65.2%)
Values are the median (IQR) or number (%), as indicated.
ASA indicates American Society of Anesthesiologists: Performance status; BMI, body mass index; HDU, high-dependency unit; IQR, interquartile range; TIVA, total
intravenous anesthesia; WHO, World Health Organization.
*P< 0.05.
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medulloblastoma had a reduced risk of developing hyper-
lactatemia compared with those with a glioblastoma.
Regression analysis showed that patients with hy-
perlactatemia the morning after surgery had longer sur-
gery durations and higher dexamethasone dose compared
with those without hyperlactatemia on the morning after
surgery. Also, after correcting for confounders, patients
with a meningioma, astrocytoma, oligodendroglioma, or
medulloblastoma had hyperlactatemia the morning after
surgery less frequently than those with glioblastoma. Fi-
nally, patients that received balanced anesthesia had hy-
perlactatemia the morning after surgery more often than
those that received TIVA.
Because the use of TIVA seemed protective for hy-
perlactatemia in both the univariate and the multivariate
analyses, we tested the use of TIVA directly on the outcome
parameters. Patients that received TIVA had a shorter
hospital length of stay (5 [IQR: 4 to 8] d) than those that
received balanced anesthesia (6 [IQR: 5 to 8] d, P= 0.007).
However, there were no signiﬁcant differences in 6-month
survival, neurological deﬁcits, or rehabilitation needs.
We performed a subgroup analysis on patients with
acidosis on arrival to the HDU; the same variables were
used in analysis. These patients had signiﬁcantly higher
BMI (26.8 [IQR: 24.0 to 32.0]) compared with those
without acidosis (25.6 [IQR: 23.2 to 28.8], P= 0.006).
The morning after surgery, these patients also had a
higher glucose (7.4 [IQR: 6.8 to 8.2] mmol/L vs. 6.9 [IQR:
6.3 to 7.9] mmol/L, P= 0.015) and lower pH (7.41 [IQR:
7.39 to 7.44] vs. 7.44 [IQR: 7.41 to 7.46], P< 0.001)
compared with those without acidosis. We found no
signiﬁcant difference for age, duration of surgery, blood
loss, ﬂuid balance, dexamethasone, or mannitol admin-
istration, glucose on HDU arrival, lactate the morning
after surgery, tumor type, ASA class, tumor side, degree
of resection or anesthetic used. Patients with acidosis on
HDU admission showed no difference in length of hos-
pital stay, 6-month survival, neurological deﬁcits or re-
habilitation needed, when compared with nonacidotic
patients.
DISCUSSION
In this study 51.8% of 496 patients had serum lactate
levels above the upper normal limit of 2.0 mmol/L on
admission to the HDU following intracranial tumor sur-
gery. Combined with normal pH values, these ﬁndings
suggest that hyperlactatemia type B was the predominant
abnormality. The morning after surgery, lactate levels had
normalized in the majority of patients. Hyperlactatemia
was not associated with reduced survival at 6 months, a
ﬁnding consistent with other studies.4–6 Although sub-
group analysis of the patients that had acidosis revealed
statistically signiﬁcant differences, it is unlikely that these
are clinically relevant.
Our study included the second largest population of
patients undergoing brain tumor resection in which factors
associated with postoperative hyperlactatemia were as-
sessed. Moreover, our database included most factors that
were highlighted in previous studies and provides support-
ing evidence for some potentially causative factors for the
development of hyperlactatemia type B after intracranial
TABLE 3. Logistic Regression Analysis of Factors Potentially Associated With Hyperlactatemia on HDU Arrival
and the Morning After Surgery
Odds Ratio (95% CI)
Hyperlactatemia on HDU Arrival (N= 257) Hyperlactatemia Day After Sugery (N= 79)
Variables Univariate Multivariate Univariate Multivariate
Age (y) 0.99 (0.98-1.01) 0.98 (0.96-0.99)* 1.00 (0.98-1.02) 0.99 (0.97-1.01)
BMI (kg/m2) 1.02 (0.99-1.06) 1.01 (0.97-1.06) 1.03 (0.99-1.08) 1.03 (0.98-1.08)
Surgery duration (h) 1.16 (1.06-1.27)* 1.25 (1.11-1.41)* 1.22 (1.09-1.35)* 1.23 (1.10-1.46)*
Blood loss (mL) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Fluid balance (mL) 1.00 (0.99-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00) 1.00 (1.00-1.00)
Total dexamethasone administered (mg) 1.03 (1.01-1.04)* 1.03 (1.01-1.04)* 1.02 (1.00-1.03)* 1.02 (1.00-1.04)*
Total mannitol administered per kilogram (g/kg) 0.87 (0.47-1.60) 0.76 (0.36-1.62) 1.24 (0.53-2.90) 1.59 (0.57-4.44)
Glucose on HDU admission (mmol/L) 1.23 (1.11-1.37)* 1.30 (1.15-1.47)* 1.12 (0.99-1.25) 1.13 (0.98-1.30)
pH on HDU admission 36.85 (0.77-1775) 7.53 (0.09-666) 2.16 (0.01-405) 0.20 (0.00-73)
Tumor type
Glioblastoma Reference Reference Reference Reference
Meningioma (WHO I-III) 0.52 (0.32-0.85)* 0.28 (0.15-0.51)* 0.76 (0.39-1.49) 0.42 (0.18-0.94)*
Astrocytoma, oligodendroglioma,
medulloblastoma
0.45 (0.24-0.85)* 0.22 (0.10-0.48)* 0.27 (0.08-0.92)* 0.20 (0.05-0.76)*
Adenoma, craniopharyngioma, cyst 0.67 (0.36-1.26) 0.53 (0.25-1.14) 0.88 (0.35-2.23) 0.87 (0.31-2.42)
Ependymoma, schwannoma,
hemangioblastoma
0.92 (0.39-2.14) 0.40 (0.15-1.10) 2.08 (0.80-5.37) 1.25 (0.41-3.84)
Metastasis 0.99 (0.56-1.73) 0.81 (0.43-1.50) 1.45 (0.72-2.89) 1.58 (0.75-3.30)
Lymphoma, other 0.59 (0.20-1.71) 0.34 (0.10-1.15) 0.34 (0.04-2.72) 0.28 (0.03-3.36)
TIVA 0.59 (0.39-0.87)* 0.50 (0.31-0.81)* 0.70 (0.42-1.18) 0.55 (0.31-0.99)*
BMI indicates body mass index; HDU, high-dependency unit; TIVA, total intravenous anesthesia; WHO, World Health Organization.
*P< 0.05.
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tumor surgery. Our ﬁnding that hyperlactatemia did not
have a negative effect on outcomes might justify less ag-
gressive management of hyperlactatemia type B in this
patient population.
After brain tumor resection, many patients are man-
aged in the immediate postoperative period in an HDU or
ICU where hyperlactatemia is typically assumed to result
from circulatory deterioration. Such hyperlactemia (type A)
requires rapid assessment and ﬂuid resuscitation, as rec-
ommended, for example, by the Surviving Sepsis Campaign
guidelines.21 Lactate-guided ﬂuid resuscitation is recom-
mended in the initial phase, regardless of the source of hy-
perlactatemia. However, research has shown that ﬂuid
overload can cause adverse effects and negative outcomes
after general surgery.22 Brallier et al6 also found that pa-
tients with elevated lactate were given approximately extra
TABLE 4. Characteristics of Patients, Divided Into 4 Groups According to Their Lactate on HDU Admission and the Morning After
Surgery
Variables
No Hyperlactatemia at
all (N= 207)
Hyperlactatemia That
Resoluted (N= 173)
Hyperlactatemia That
Persisted (N= 65)
Normal Lactate That
Became Elevated
(N= 14) P
Age (y) 58.6 (46.9-69.3) 58.8 (47.4-67.4) 56.7 (44.3-69.0) 64.7 (58.9-73.4) 0.128
BMI (kg/m2) 25.7 (23.2-28.7) 25.5 (23.2-29.2) 26.8 (24.4-30.5) 26.8 (24.5-30.8) 0.225
Surgery duration (h:min) 4:32 (3:38-5:42) 4:52 (3:57-5:58) 5:29 (3:50-7:24) 4:46 (3:25-6:47) 0.017*
Blood loss (mL) 200 (100-400) 300 (150-500) 350 (200-650) 150 (88-363) 0.006*
Fluid balance (mL) 357 (−54 to 740) 170 (−422 to 702) 304 (−358 to 655) 574 (−408 to 887) 0.086
Total dexamethasone
administered (mg)
16 (16-20) 16 (16-56) 16 (16-55) 16 (16-48) < 0.000*
Total mannitol administered (g) 30 (0-45) 30 (15-45) 30 (15-45) 45 (23-45) 0.520
Total mannitol administered
per kilogram (g/kg)
0.41 (0.00-0.64) 0.38 (0.19-0.53) 0.39 (0.16-0.57) 0.41 (0.25-0.68) 0.886
Glucose on HDU admission
(mmol/L)
7.9 (7.0-8.8) 8.4 (7.4-9.7) 8.6 (7.6-9.5) 8.7 (7.7-10.5) < 0.000*
Lactate on HDU admission
(mmol/L)
1.4 (1.0-1.7) 2.8 (2.3-3.5) 3.2 (2.8-3.8) 1.4 (1.3-1.7) < 0.000*
pH on HDU admission 7.39 (7.36-7.41) 7.39 (7.37-7.42) 7.40 (7.37-7.42) 7.41 (7.35-7.44) 0.365
Glucose morning after
admission (mmol/L)
6.9 (6.2-7.7) 6.9 (6.2-7.7) 7.9 (6.9-8.8) 7.8 (6.8-9.2) < 0.000*
Lactate morning after
admission (mmol/L)
1.1 (0.9-1.5) 1.5 (1.2-1.8) 2.5 (2.2-2.9) 2.3 (1.2-2.6) < 0.000*
pH morning after admission 7.43 (7.41-7.45) 7.44 (7.41-7.46) 7.43 (7.42-7.46) 7.43 (7.42-7.45) 0.024*
Tumor type 0.015*
Glioblastoma 47 (22.7%) 59 (34.1%) 19 (29.2%) 5 (35.7%)
Meningioma (WHO I-III) 66 (31.9%) 38 (22.0%) 15 (23.1%) 3 (21.4%)
Astrocytoma,
oligodendroglioma,
medulloblastoma
30 (14.5%) 20 (11.6%) 3 (4.6%) 0 (0%)
Adenoma,
craniopharyngioma, cyst
23 (11.1%) 12 (6.9%) 7 (10.8%) 0 (0%)
Ependymoma, schwannoma,
hemangioblastoma
8 (3.9%) 9 (5.2%) 5 (7.7%) 3 (21.4%)
Metastasis 27 (13.0%) 28 (16.2%) 16 (24.6%) 2 (14.3%)
Lymphoma, other 6 (2.9%) 7 (4.0%) 0 (0%) 1 (7.1%)
ASA class 0.351
I 27 (13.0%) 30 (17.3%) 14 (21.5%) 2 (14.3%)
II 141 (68.1%) 100 (57.8%) 37 (56.9%) 6 (42.9%)
III 35 (16.9%) 41 (23.7%) 14 (21.5%) 6 (42.9%)
IV 3 (1.4%) 2 (1.2%) 0 (0%) 0 (0%)
V 1 (0.5%) 0 (0%) 0 (0%) 0 (0%)
Tumor side 0.160
Left 90 (43.5%) 67 (38.7%) 27 (41.5%) 3 (21.4%)
Right 85 (41.1%) 81 (46.8%) 26 (40.0%) 11 (78.6%)
Both (eg, pituitary) 32 (15.5%) 25 (14.5%) 12 (18.5%) 0 (0%)
Degree of resection 0.169
Complete resection 53 (25.9%) 39 (22.5%) 12 (18.8%) 1 (7.1%)
Nearly complete resection 30 (14.6%) 19 (11.0%) 4 (6.3%) 1 (7.1%)
Tumor remnant 122 (59.5%) 115 (66.5%) 48 (75.0%) 12 (85.7%)
TIVA 153 (76.1%) 117 (68.4%) 41 (64.1%) 9 (69.2%) 0.200
Values are the median (IQR) or number (%), as indicated.
ASA indicates American Society of Anesthesiologists: Performance status; HDU, High-dependency unit; IQR, Interquartile range; TIVA, total intravenous anesthesia;
WHO, World Health Organization.
*P< 0.05.
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1 L of crystalloids. A more restrictive ﬂuid management of
hyperlactatemia, particularly in patients undergoing neuro-
surgery, could increase patient safety and potentially reduce
complications and costs. Finally, in some patients, control-
ling hyperglycemia can reduce serum lactate levels. How-
ever, aggressive management of hyperglycemia also
increases the risk of hypoglycemia-related incidents and
complications.23 Therefore, accepting hyperglycemia at
the cost of apparently harmless hyperlactatemia seems
appropriate.
Lactic acid dehydrogenase (LDH) is a tetrameric
enzyme, composed of H and M subunits. Five isoforms
exist; LDH1 and LDH2 are speciﬁcally expressed in the
heart and LDH5 in liver and muscle.24 A previous Japa-
nese study found that corticosteroid administration ele-
vated heart-speciﬁc LDH1 and LDH2 levels.25 In contrast,
propofol has been shown to inhibit the release of LDH
and reduce lactate accumulation in cell cultures treated
with lipopolysaccharide.26,27 Furthermore, in vitro data
revealed that hyperlactatemia occurred in rodent brain
and liver samples more often with volatile than with
propofol anesthesia.28,29 That ﬁnding was conﬁrmed in
humans during prolonged spinal surgery30 and carotid
endarterectomy.31 Taken together, these ﬁndings suggest
that the use of propofol might be protective against hy-
perlactatemia. However, this notion must be considered in
the context of concerns about PRIS, which is a potentially
hazardous complication of propofol administration.32
PRIS is characterized by early metabolic acidosis, which
can lead to cardiac failure. There is no published evidence
that opioids might contribute to hyperlactatemia in vitro
or in vivo.
Another potential contributing factor to elevated
serum lactate is a high BMI. Garavaglia et al10 hypothe-
sized that muscle ischemia and tissue breakdown caused
hyperlactatemia, which was potentially aggravated by a
high BMI. However, we did not ﬁnd that BMI was an
independent risk factor for the development of post-
operative hyperlactatemia. However, increases in BMI
can lead to insulin resistance,33 and this may contribute to
the increased serum lactate levels observed in obese pa-
tients.
In contrast to the aforementioned study by
Garavaglia et al,10 a longer surgery duration was asso-
ciated with elevated serum lactate in our study. This might
be explained by immobility during anesthesia, since pro-
longed immobility can cause regional hypoperfusion and
tissue breakdown. In addition, the positioning of the pa-
tient, supine or prone, can increase tissue stress, and thus,
stimulate anaerobic metabolism.
Recent studies have suggested that lactate can have a
neuroprotective role because it serves as a substrate for
oxidation under certain conditions. For example, hypertonic
sodium lactate can modulate cerebral metabolism34,35 and
potentially attenuate brain damage after traumatic injury.36
Although this ﬁnding is controversial37 and requires more
research, it is interesting to consider that an innate pro-
tective mechanism might be activated during iatrogenic
brain injury (ie, a craniotomy).
Increased blood loss and less positive ﬂuid balance are
indications of a change in intravascular volume. Although
both blood loss and ﬂuid balance remained within normal
clinical limits in our study, taken together, these factors
could implicate a relative hypovolemia and, potentially,
impaired oxygen delivery to tissues in patients with elevated
serum lactate. However, in the multiple regression analysis
these factors lost signiﬁcance as independent predictors.
Moreover, impaired oxygen delivery should induce meta-
bolic acidosis, which was infrequently observed. Our sub-
analysis of patients with acidosis showed that blood loss and
ﬂuid balance were not signiﬁcantly associated with acidosis.
We performed additional analyses for patients with
hyperlactatemia the day after surgery and the associated
factors were similar to those for elevated lactate on ad-
mission to HDU. We also provided a detailed description
of the characteristics of the patients divided into 4 groups:
those with hyperlactatemia on HDU admission that re-
solved or persisted, and those with normal lactate on ad-
mission that remained normal or became elevated by the
following morning. Because the number of patients is
small for these 4 groups, we lost power for statistical
analysis.
Brallier et al6 found that intraoperative hyper-
lactatemia was associated with longer hospital stay and
more neurological deﬁcits. Although our study conﬁrmed
the association with hospital stay, we found no difference
in neurological deﬁcits or rehabilitation needs of patients
with hyperlactemia. Whether it is the hyperlactatemia it-
self, or the treatment of the high lactate levels, that is
responsible for the increased length of hospital stay re-
mains unclear. Nonetheless, this outcome is clinically
relevant because longer hospital stay leads to higher health
care costs and additional patient exposure to the high-risk
hospital environment.
Brallier et al6 hypothesized that regional hypo-
perfusion during surgery is a cause of hyperlactatemia.
This should be accompanied by (cerebrospinal ﬂuid)
acidosis but, unfortunately, no data on pH were reported
to conﬁrm that hypothesis. An important difference be-
tween the present study and that by Brallier and colleagues
is the timing of blood sampling. Brallier and colleagues
sampled blood intraoperatively whereas we sampled blood
postoperatively on admission to the HDU.
A few studies have attempted to correlate tumor vol-
ume and elevated serum lactate, but the results are
conﬂicting.5,14,38 Some authors have suggested that lactate
can be used as a biomarker for tumor progression and
therapy response in glioblastoma patients,38 whereas others
have been unable to conﬁrm this ﬁnding.5 Our data dem-
onstrate an association between tumor type (glioblastoma)
and hyperlactatemia at HDU admission, but we did not
measure tumor volume.
An important limitation of our study was its retro-
spective design. Consequently, we could not investigate
some potentially important factors such as preoperative
serum lactate or patient positioning. Moreover, we could
not avoid evident biases. Another limitation was that the
anesthesia technique was not standardized and this could
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have led to differences in the anesthesia provided in
terms of type and dosing of drugs and ﬂuid management.
Finally, an anesthesia record was not available in some
patients’ ﬁles and, thus, some data were missing.
CONCLUSIONS
Hyperlactatemia type B occurred in over 50% of
almost 500 patients that underwent intracranial tumor
resection. Age, surgery duration, amount of dex-
amethasone administered, blood glucose, and glio-
blastoma tumor type were associated with elevated serum
lactate on admission to the HDU. Patients that received
TIVA had hyperlactatemia less frequently than those that
received inhalational agents. The development of hyper-
lactatemia did not affect 6-month survival, but was as-
sociated with longer hospital lengths of stay. On the basis
of our data, we were unable to determine whether the
prolonged hospital stay was due to the hyperlactatemia
itself or to its treatment. There was no association be-
tween elevated serum lactate and worsening of neuro-
logical status or need for rehabilitation therapy.
Prospective trials are necessary to conﬁrm the potential
associations with hyperlactemia identiﬁed in this study.
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